Laboratorios Rovi (BME: ROVI) net income
Laboratorios Rovi reported a net profit of €140.4m for fiscal 2025, 2.6% more than in fiscal 2024 (€136.9m). Its net margin was 18.9%. Earnings per share were €2.75.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | €140.4m | +2.6% | 18.9% | €2.75 |
| 2024 | €136.9m | −19.6% | 17.9% | €2.67 |
| 2023 | €170.3m | −14.7% | 20.5% | €3.20 |
| 2022 | €199.7m | +30.4% | 24.4% | €3.73 |
| 2021 | €153.1m | +150.7% | 23.6% | €2.76 |
| 2020 | €61.1m | — | 14.5% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of euros, except per-share amounts.
Questions about the net income of Laboratorios Rovi
- How much did Laboratorios Rovi earn in fiscal 2025?
- Laboratorios Rovi reported a net profit of €140.4m for fiscal 2025. In fiscal 2024 it reported a net profit of €136.9m.
- What are the earnings per share of Laboratorios Rovi?
- They were €2.75 in fiscal 2025, compared with €2.67 in fiscal 2024.
- What is the net margin of Laboratorios Rovi?
- In fiscal 2025 its net profit was 18.9% of its revenue.
- What was the most profitable year for Laboratorios Rovi?
- Of its last 6 fiscal years, fiscal 2022, with €199.7m.
- Where do the figures for Laboratorios Rovi come from?
- From the report Laboratorios Rovi files every year in the European single electronic format (ESEF), the same one the CNMV, the Spanish regulator, receives. Each fiscal year links to its filing.
Where each figure comes from
From the annual report Laboratorios Rovi files every year in the European single electronic format (ESEF). The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021. More on Laboratorios Rovi: the Laboratorios Rovi page · annual accounts · revenue · dividends paid.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.